# Post-authorization Safety Study in CKD Subjects Receiving HX575 i.v.

> **NCT00632125** · PHASE4 · COMPLETED · sponsor: **Sandoz** · enrollment: 1695 (actual)

## Conditions studied

- Chronic Kidney Disease

## Interventions

- **DRUG:** HX575 recombinant human erythropoietin alfa

## Key facts

- **NCT ID:** NCT00632125
- **Lead sponsor:** Sandoz
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2010-03
- **Final completion:** 2010-09
- **Target enrollment:** 1695 (ACTUAL)
- **Last updated:** 2017-07-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00632125

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00632125, "Post-authorization Safety Study in CKD Subjects Receiving HX575 i.v.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00632125. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*